Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 6/2009

01.12.2009 | Therapy In Practice

Ichthyosis

Clinical Manifestations and Practical Treatment Options

verfasst von: Vinzenz Oji, Heiko Traupe

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Ichthyoses constitute a large group of cornification disorders that affect the entire integument. The skin is characterized by visible scaling and in many cases by inflammation, for example, in bullous/keratinopathic ichthyosis or Netherton syndrome. From the viewpoint of classification it is useful to distinguish nonsyndromic from syndromic types of ichthyosis. Ichthyosis vulgaris and recessive X-linked ichthyosis are common disorders—often of delayed onset, in contrast to congenital ichthyoses, which belong to the group of rare diseases and present at birth with either the features of collodion membrane or congenital ichthyosiform erythroderma.
The diagnostic steps are based on clinical data, analyses such as the steroid sulfatase activity test, skin biopsies, and genetic results. However, the dramatic increase in knowledge about the pathophysiology of these conditions has not led to a curative therapy so far. The therapeutic management is multidisciplinary and involves ichthyosis patient organizations in many countries. The mainstay of treatment remains with moisturizing creams containing, for example, urea, lactic acid and other humectants and keratolytics, regular bathing, and mechanical scale removal. Patients with lamellar ichthyosis or ichthyosiform erythroderma in particular profit from oral therapy with retinoids or retinoic acid metabolism-blocking agents.
Literatur
1.
Traupe H. The ichthyosis: a guide to clinical diagnosis, genetic counseling, and therapy. Berlin: Springer Verlag, 1989: 111–34
2.
Oji V, Traupe H. Ichthyoses: differential diagnosis and molecular genetics. Eur J Dermatol 2006; 16: 349–59PubMed
3.
4.
5.
Classification of congenital ichthyosis. First World Conference on Ichthyosis; 2007 Aug 31-Sep 2; Münster
6.
Elias PM, Williams ML, Holleran WM, et al. Thematic review series: skin lipids. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 2008; 49: 697–714
7.
Schmuth M, Gruber R, Elias PM, et al. Ichthyosis update: towards a functiondriven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. Adv Dermatol 2007; 23: 231–56PubMedCrossRef
8.
DiGiovanna JJ. Ichthyosiform dermatoses: so many discoveries, so little progress. J Am Acad Dermatol 2004; 51: S31–4CrossRef
9.
10.
Wells RS, Jennings MC. X-linked ichthyosis and ichthyosis vulgaris: clinical and genetic distinctions in a second series of families. JAMA 1967; 202: 485–8PubMedCrossRef
11.
Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006; 38: 337–42PubMedCrossRef
12.
Liao H, Waters AJ, Goudie DR, et al. Filaggrin mutations are genetic modifying factors exacerbating X-linked ichthyosis. J Invest Dermatol 2007; 127: 2795–8PubMedCrossRef
13.
Webster D, France JT, Shapiro LJ, et al. X-linked ichthyosis due to steroidsulphatase deficiency. Lancet 1978; I: 70–2
14.
Ballabio A, Parenti G, Carrozzo R, et al. Isolation and characterization of a steroid sulfatase cDNA clone: genomic deletions in patients with X-chromosome-linked ichthyosis. Proc Natl Acad Sci USA 1987; 84: 4519–23PubMedCrossRef
15.
Hernandez-Martin A, Gonzalez-Sarmiento R, De Unamuno P. X-linked ichthyosis: an update. Br J Dermatol 1999; 141: 617–27PubMedCrossRef
16.
Akiyama M, Sakai K, Sato T, et al. Compound heterozygous ABCA12 mutations including a novel nonsense mutation underlie harlequin ichthyosis. Dermatology 2007; 215: 155–9PubMedCrossRef
17.
Kelsell DP, Norgett EE, Unsworth H, et al. Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet 2005; 76: 794–803PubMedCrossRef
18.
Lefevre C, Audebert S, Jobard F, et al. Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet 2003; 12: 2369–78PubMedCrossRef
19.
Akiyama M, Sawamura D, Shimizu H. The clinical spectrum of nonbullous congenital ichthyosiform erythroderma and lamellar ichthyosis. Clin Exp Dermatol 2003; 28: 235–40PubMedCrossRef
20.
Oji V, Hautier JM, Ahvazi B, et al. Bathing suit ichthyosis is caused by transglutaminase-1 deficiency: evidence for a temperature-sensitive phenotype. Hum Mol Genet 2006; 15: 3083–97PubMedCrossRef
21.
Raghunath M, Hennies HC, Ahvazi B, et al. Self-healing collodion baby: a dynamic phenotype explained by a particular transglutaminase-1 mutation. J Invest Dermatol 2003; 120: 224–8PubMedCrossRef
22.
Harting M, Brunetti-Pierri N, Chan CS, et al. Self-healing collodionmembrane and mild nonbullous congenital ichthyosiform erythroderma due to 2 novel mutations in the ALOX12B gene. Arch Dermatol 2008; 144: 351–6PubMedCrossRef
23.
Lefevre C, Bouadjar B, Ferrand V, et al. Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet 2006; 15: 767–76PubMedCrossRef
24.
Jobard F, Lefevre C, Karaduman A, et al. Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet 2002; 11: 107–13PubMedCrossRef
25.
Lefevre C, Bouadjar B, Karaduman A, et al. Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet 2004; 13: 2473–82PubMedCrossRef
26.
Compton JG, DiGiovanna JJ, Santucci SK, et al. Linkage of epidermolytic hyperkeratosis to the type II keratin gene cluster on chromosome 12q. Nat Genet 1992; 1: 301–5PubMedCrossRef
27.
Rothnagel JA, Dominey AM, Dempsey LD, et al. Mutations in the rod domains of keratins 1 and 10 in epidermolytic hyperkeratosis. Science 1992; 257: 1128–30PubMedCrossRef
28.
Steijlen PM, Perret CM, Schuurmans Stekhoven JH, et al. Ichthyosis bullosa of Siemens: further delineation of the phenotype. Arch Dermatol Res 1990; 282: 1–5PubMedCrossRef
29.
Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoAhydroxylase gene. Nat Genet 1997; 17: 190–3PubMedCrossRef
30.
Jansen GA, Waterham HR, Wanders RJ. Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). Hum Mutat 2004; 23: 209–18PubMedCrossRef
31.
Eldjarn L, Try K, Stokke O, et al. Dietary effects on serum-phytanic-acid levels and on clinical manifestations in heredopathia atactica polyneuritiformis. Lancet 1966; I: 691–3CrossRef
32.
Sprecher E, Chavanas S, DiGiovanna JJ, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol 2001; 117: 179–87PubMedCrossRef
33.
Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, causeNetherton syndrome. Nat Genet 2000; 25: 141–2PubMedCrossRef
34.
Komatsu N, Takata M, Otsuki N, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol 2002; 118: 436–43PubMedCrossRef
35.
De Laurenzi V, Rogers GR, Hamrock DJ, et al. Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet 1996; 12: 52–7PubMedCrossRef
36.
37.
Lefevre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin- Dorfman syndrome. Am J Hum Genet 2001; 69: 1002–12PubMedCrossRef
38.
Angelini C, Philippart M, Borrone C, et al. Multisystem triglyceride storage disorder with impaired long-chain fatty acid oxidation. Ann Neurol 1980; 7: 5–10PubMedCrossRef
39.
Faghri S, Tamura D, Kraemer KH, et al. Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. J Med Genet 2008; 45: 609–21PubMedCrossRef
40.
Patel N, Spencer LA, English III JC, et al. Acquired ichthyosis. J Am Acad Dermatol 2006; 55: 647–56PubMedCrossRef
41.
Dale BA, Holbrook KA, Fleckman P, et al. Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules. J Invest Dermatol 1990; 94: 6–18PubMedCrossRef
42.
Elias PM, Williams ML. Neutral lipid storage disease with ichthyosis: defective lamellar body contents and intracellular dispersion. Arch Dermatol 1985; 121: 1000–8PubMedCrossRef
43.
Dahlqvist J, Klar J, Hausser I, et al. Congenital ichthyosis: mutations in ichthyin are associated with specific structural abnormalities in the granular layer of epidermis. J Med Genet 2007; 44: 615–20PubMedCrossRef
44.
Ishida-Yamamoto A, Richard G, Takahashi H, et al. In vivo studies of mutant keratin 1 in ichthyosis hystrix Curth-Macklin. J Invest Dermatol 2003; 120: 498–500PubMedCrossRef
45.
Ong C, O’Toole EA, Ghali L, et al. LEKTI demonstrable by immunohistochemistry of the skin: a potential diagnostic skin test for Netherton syndrome. Br J Dermatol 2004; 151: 1253–7PubMedCrossRef
46.
Raghunath M, Tontsidou L, Oji V, et al. SPINK5 and Netherton syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol 2004; 123: 474–83PubMedCrossRef
47.
Raghunath M, Hennies HC, Velten F, et al. A novel in situ method for the detection of deficient transglutaminase activity in the skin. Arch Dermatol Res 1998; 290: 621–7PubMedCrossRef
48.
Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C, et al. Oral liarozole versus acitretin in the treatment of ichthyosis: a phase II/III multicentre, doubleblind, randomized, active-controlled study. Br J Dermatol 2007; 156: 965–73PubMedCrossRef
49.
Okano M. Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis. Dermatology 2001; 202: 116–8PubMedCrossRef
50.
Lucker GP, Heremans AM, Boegheim PJ, et al. Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole. Br J Dermatol 1997; 136: 71–5PubMedCrossRef
51.
Lucker GP, Verfaille CJ, Heremans AM, et al. Topical liarozole in ichthyosis: a double-blind, left-right comparative study followed by a long-term open maintenance study. Br J Dermatol 2005; 152: 566–9PubMedCrossRef
52.
Kuster W, Bohnsack K, Rippke F, et al. Efficacy of urea therapy in children with ichthyosis: a multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology 1998; 196: 217–22PubMedCrossRef
53.
Kragballe K, Steijlen PM, Ibsen HH, et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization: results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995; 131: 556–60PubMedCrossRef
54.
Kempers S, Katz HI, Wildnauer R, et al. An evaluation of the effect of an alpha hydroxy acid-blend skin cream in the cosmetic improvement of symptoms of moderate to severe xerosis, epidermolytic hyperkeratosis, and ichthyosis. Cutis 1998; 61: 347–50PubMed
55.
Ganemo A, Virtanen M, Vahlquist A. Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations. Br J Dermatol 1999; 141: 1027–32PubMedCrossRef
56.
DiGiovanna JJ, Robinson-Bostom L. Ichthyosis: etiology, diagnosis, and management. Am J Clin Dermatol 2003; 4: 81–95PubMedCrossRef
57.
Kuster W. Ichthyoses: suggestions for an improved therapy. Deutsches Ärzteblatt 2006; 103: 1484–9
58.
Shwayder T. Disorders of keratinization: diagnosis and management. Am J Clin Dermatol 2004; 5: 17–29PubMedCrossRef
59.
Traupe H, Burgdorf WHC. Treatment of ichthyosis: there is always something you can do! In memoriam: Wolfgang Küster. Am Acad Dermatol 2007; 57: 542–7CrossRef
60.
Vahlquist A, Ganemo A, Virtanen M. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 2008; 88: 4–14PubMedCrossRef
61.
Elias PM, Williams ML, Holleran WM, et al. Thematic review series: skin lipids. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 2008; 49: 697–714
62.
Hofmann B, Stege H, Ruzicka T, et al. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999; 141: 642–6PubMedCrossRef
63.
Nguyen V, Cunningham BB, Eichenfield LF, et al. Treatment of ichthyosiform diseases with topically applied tazarotene: risk of systemic absorption. J Am Acad Dermatol 2007; 57 (5 Suppl.): S123–5CrossRef
64.
Cotellessa C, Cuevas-Covarrubias SA, Valeri P, et al. Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the STS gene. Acta Derm Venereol 2005; 85: 346–8PubMed
65.
Yamamura S, Kinoshita Y, Kitamura N, et al. Neonatal salicylate poisoning during the treatment of a collodion baby. Clin Pediatr (Phila) 2002; 41: 451–2CrossRef
66.
Singh S, Bhura M, Maheshwari A, et al. Successful treatment of harlequin ichthyosis with acitretin. Int J Dermatol 2001; 40: 472–3PubMedCrossRef
67.
Lawlor F, Peiris S. Harlequin fetus successfully treated with etretinate. Br J Dermatol 1985; 112: 585–90PubMedCrossRef
68.
Ozturk A, Caksen H, Cetin N, et al. A retrospective study on 16 collodion babies. Turk J Pediatr 1997; 39: 55–9PubMed
69.
Hachem JP, Houben E, Crumrine D, et al. Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 2006; 126: 2074–86PubMedCrossRef
70.
Haenssle HA, Finkenrath A, Hausser I, et al. Effective treatment of severe thermodysregulation by oral retinoids in a patient with recessive congenital lamellar ichthyosis. Clin Exp Dermatol 2008; 33 (5): 578–81PubMedCrossRef
71.
Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153: 1067–8PubMedCrossRef
72.
Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747–50PubMed
73.
Lacour M, Mehta-Nikhar B, Atherton DJ, et al. An appraisal of acitretin therapy in children with inherited disorders of keratinization. Br J Dermatol 1996; 134: 1023–9PubMedCrossRef
74.
Steijlen PM, Van Dooren-Greebe RJ, Happle R, et al. Ichthyosis bullosa of Siemens responds well to low-dosage oral retinoids. Br J Dermatol 1991; 125: 469–71PubMedCrossRef
75.
Berth-Jones J, Todd G, Hutchinson PE, et al. Treatment of psoriasis with oral liarozole: a dose-ranging study. Br J Dermatol 2000; 143: 1170–6PubMedCrossRef
76.
Akiyama M, Titeux M, Sakai K, et al. DNA-based prenatal diagnosis of harlequin ichthyosis and characterization of ABCA12 mutation consequences. J Invest Dermatol 2007; 127: 568–73PubMedCrossRef
77.
Bitoun E, Bodemer C, Amiel J, et al. Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis. Prenat Diagn 2002; 22: 121–6PubMedCrossRef
78.
Rothnagel JA, Lin MT, Longley MA, et al. Prenatal diagnosis for keratin mutations to exclude transmission of epidermolytic hyperkeratosis. Prenat Diagn 1998; 18: 826–30PubMedCrossRef
79.
Fassihi H, Eady RA, Mellerio JE, et al. Prenatal diagnosis for severe inherited skin disorders: 25 years’ experience. Br J Dermatol 2006; 154: 106–13PubMedCrossRef
Metadaten
Titel
Ichthyosis
Clinical Manifestations and Practical Treatment Options
verfasst von
Vinzenz Oji
Heiko Traupe
Publikationsdatum
01.12.2009
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2009
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/11311070-000000000-00000

Weitere Artikel der Ausgabe 6/2009

American Journal of Clinical Dermatology 6/2009 Zur Ausgabe

Original Research Article

Patient Characteristics in Behçet Disease

Short Communication

Impact of Psoriasis on Patients’ Work and Productivity

Case Report

Giant Melanoma and Depression

Review Article

Topical Clobetasol Propionate in the Treatment of Psoriasis

Therapy in Practice

Cutaneous Lupus Erythematosus

Adis Profile Report

Alitretinoin in Severe Chronic Hand Eczema †

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise